Recent drug developments have focused on restoring CFTR function; these therapies significantly improve lung function and reduce exacerbations in CF patients (Wainwright et al., 2015; Rowe et al., 2017; Davies et al., 2018; Keating et al., 2018). The gene discussed is CFTR; the disease is cystic fibrosis.